ID   MCF10A-ERBB2m-5
AC   CVCL_C7QT
DR   CancerTools; 161194
DR   Wikidata; Q117704676
RX   PubMed=30787176;
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 3430; ERBB2 (with p.Ala775_Gly776insTyrValMetAla).
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008359.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0598 ! MCF-10A
SX   Female
AG   36Y
CA   Spontaneously immortalized cell line
DT   Created: 21-03-23; Last updated: 29-06-23; Version: 2
//
RX   PubMed=30787176; DOI=10.1158/1535-7163.MCT-18-1085;
RA   Irie H., Ito K., Fujioka Y., Oguchi K., Fujioka A., Hashimoto A.,
RA   Ohsawa H., Tanaka K., Funabashi K., Araki H., Kawai Y., Shimamura T.,
RA   Wadhwa R., Ohkubo S., Matsuo K.;
RT   "TAS0728, a covalent-binding, HER2-selective kinase inhibitor shows
RT   potent antitumor activity in preclinical models.";
RL   Mol. Cancer Ther. 18:733-742(2019).
//